首页> 美国卫生研究院文献>other >Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

【2h】

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

机译：Capecitabine的II期介入研究（N0337）与血列林和曲妥珠单抗组合的HER2阳性转移性乳腺癌的第一或二线治疗：北中央癌症治疗组试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe conducted a multi-institutional phase II study of capecitabine in combination with vinorelbine and trastuzumab in patients eligible to receive first- or second-line treatment for human epidermal growth factor receptor type 2 (HER2)– positive metastatic breast cancer (MBC).

机译：背景技术在有资格接受人表皮生长因子受体2（HER2）阳性转移性乳腺癌（MBC）的患者中，将Capecitabine与血肠和曲妥珠单抗的组合进行了多制剂期II研究。

著录项

期刊名称 other
作者
Winston W. Tan; Jacob B. Allred; Muhammad Salim; Patrick Flynn; Paul A. S. Fishkin; Philip J. Stella; Martin Wiesenfeld; Albert M. Bernath; Tom R. Fitch; Edith A. Perez;
展开▼
作者单位

展开▼
年(卷),期 -1(12),2
年度 -1
页码 81–86
总页数 18
原文格式 PDF
正文语种
中图分类
关键词
capecitabine combination chemotherapy metastatic breast cancer trastuzumab vinorelbine;

机译：卡培他滨;联合化疗;转移性乳腺癌;曲妥珠单抗;长春瑞滨;

相似文献

外文文献
中文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: A north central cancer treatment group trial [J] . TanW.W., AllredJ.B., SalimM., Clinical breast cancer . 2012,第2期

机译：卡培他滨联合长春瑞滨和曲妥珠单抗用于HER2阳性转移性乳腺癌的一线或二线治疗的II期介入研究（N0337）
3. 2124 POSTER Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial [J] . A.Chan, V.Ganju, D.Becquart, European Journal of Cancer Supplements . 2007,第4期

机译：2124 POSTER口服长春瑞滨，卡培他滨和曲妥珠单抗的三联组合作为HER2阳性转移性乳腺癌（MBC）的一线治疗：一项国际II期试验的最新结果
4. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. [J] . Arlene Chan, Pier-Franco Conte, Lubos Petruzelka, Anticancer Research: International Journal of Cancer Research and Treatment . 2013,第6期

机译：口服长春瑞滨，卡培他滨和曲妥珠单抗三联疗法作为HER2阳性转移性乳腺癌的一线治疗的II期研究。
5. Efficacy of combination chemotherapy with docetaxel and irinotecan as first- or second-line treatment for advanced gastric cancer [C] . K. Sugiyama, A. Ishikawa, T. Watanabe International Gastric Cancer Congress . 2009

机译：组合化疗与多西紫杉醇和伊替康的疗效，作为晚期胃癌的第一或二线治疗
6. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
7. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
8. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

摘要

著录项

相似文献

相关主题

期刊订阅